Malarone

Atovaquone/proguanil, the active ingredient in Malarone, is an antimalarial presented as an oral tablet for oral use. It is indicated for the prevention of malaria in travelers and for the treatment of acute uncomplicated malaria caused by Plasmodium falciparum and Plasmodium vivax, and is marketed in the European Union meeting GMP quality standards.

GNH USA supplies Malarone as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable supply chains and regulatory compliance.

Malarone is used in the antimalarial therapeutic class to prevent and treat malaria infections.

- Prevention of malaria (traveler prophylaxis): provides protective chemoprophylaxis for individuals traveling to endemic regions. - Acute uncomplicated malaria (Plasmodium falciparum): rapidly clears parasitemia and resolves symptoms. - Acute uncomplicated malaria (Plasmodium vivax): effective in eliminating blood‑stage parasites and reducing disease recurrence.

Malarone may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea - Headache - Abdominal pain - Vomiting - Loss of appetite

Serious or Rare Side Effects: - Severe skin reactions such as Stevens‑Johnson syndrome - Hepatic injury or elevated liver enzymes - Hemolytic anemia in patients with G6PD deficiency - Anaphylactic or other severe allergic reactions

Before prescribing Malarone, clinicians should consider several safety precautions.

- Hypersensitivity assessment: confirm no known allergy to atovaquone, proguanil or related compounds. - Renal and hepatic function: evaluate kidney and liver status, adjust use if impairment is present. - Pregnancy and lactation: review risks and benefits, as safety data are limited. - Concomitant medications: check for potential drug‑drug interactions that may affect efficacy or toxicity. - Monitoring: observe patients for signs of severe skin reactions, liver dysfunction, or hemolysis. - Store at ambient temperature: keep tablets in the original container, protect from moisture and excessive heat.

Malarone can interact with other medicines, requiring attention to avoid reduced effectiveness or increased toxicity.

Major Interactions (Avoid): - Rifampicin: induces metabolism and markedly reduces atovaquone levels. - Protease inhibitors (e.g., lopinavir/ritonavir): decrease atovaquone exposure. - Certain antiepileptic drugs (e.g., carbamazepine, phenytoin): lower plasma concentrations of both components.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, requiring INR monitoring. - Oral contraceptives: efficacy may be reduced, advise additional contraceptive measures. - Statins (e.g., simvastatin): increased risk of myopathy, monitor muscle symptoms.